Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome)

Rolando Cimaz, P. L. Meroni, Y. Shoenfeld

Research output: Contribution to journalArticle

Abstract

The antiphospholipid syndrome (APS) is defined by the presence of antiphospholipid antibodies (aPL), demonstrated by ELISAs for antibodies against phospholipids and associated phospholipid-binding cofactor proteins and/or a circulating lupus anticoagulant (LA) together with diverse systemic clinical manifestations such as thrombosis, and recurrent spontaneous abortions. According to the criteria set out in Sydney the only neurological manifestations that can be suitable as APS classification criteria are ischemic events (stroke and transient ischemic attacks). However, other neurological manifestations, including seizures in particular, have been repeatedly reported in APS patients. The present review will summarize recent research on the association of aPL, as well as other autoantibodies, with seizure disorders, with or without concomitant SLE.

Original languageEnglish
Pages (from-to)191-197
Number of pages7
JournalLupus
Volume15
Issue number4
DOIs
Publication statusPublished - 2006

Fingerprint

Antiphospholipid Syndrome
Systemic Lupus Erythematosus
Epilepsy
Antiphospholipid Antibodies
Neurologic Manifestations
Phospholipids
Lupus Coagulation Inhibitor
Habitual Abortion
Transient Ischemic Attack
Spontaneous Abortion
Autoantibodies
Carrier Proteins
Seizures
Thrombosis
Enzyme-Linked Immunosorbent Assay
Stroke
Antibodies
Research

Keywords

  • Antiphospholipid
  • Autoantibodies
  • Autoimmune
  • Epilepsy
  • Seizures
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). / Cimaz, Rolando; Meroni, P. L.; Shoenfeld, Y.

In: Lupus, Vol. 15, No. 4, 2006, p. 191-197.

Research output: Contribution to journalArticle

@article{fc30bd2c40e24d4f9c5783056bbb268a,
title = "Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome)",
abstract = "The antiphospholipid syndrome (APS) is defined by the presence of antiphospholipid antibodies (aPL), demonstrated by ELISAs for antibodies against phospholipids and associated phospholipid-binding cofactor proteins and/or a circulating lupus anticoagulant (LA) together with diverse systemic clinical manifestations such as thrombosis, and recurrent spontaneous abortions. According to the criteria set out in Sydney the only neurological manifestations that can be suitable as APS classification criteria are ischemic events (stroke and transient ischemic attacks). However, other neurological manifestations, including seizures in particular, have been repeatedly reported in APS patients. The present review will summarize recent research on the association of aPL, as well as other autoantibodies, with seizure disorders, with or without concomitant SLE.",
keywords = "Antiphospholipid, Autoantibodies, Autoimmune, Epilepsy, Seizures, Systemic lupus erythematosus",
author = "Rolando Cimaz and Meroni, {P. L.} and Y. Shoenfeld",
year = "2006",
doi = "10.1191/0961203306lu2272rr",
language = "English",
volume = "15",
pages = "191--197",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome)

AU - Cimaz, Rolando

AU - Meroni, P. L.

AU - Shoenfeld, Y.

PY - 2006

Y1 - 2006

N2 - The antiphospholipid syndrome (APS) is defined by the presence of antiphospholipid antibodies (aPL), demonstrated by ELISAs for antibodies against phospholipids and associated phospholipid-binding cofactor proteins and/or a circulating lupus anticoagulant (LA) together with diverse systemic clinical manifestations such as thrombosis, and recurrent spontaneous abortions. According to the criteria set out in Sydney the only neurological manifestations that can be suitable as APS classification criteria are ischemic events (stroke and transient ischemic attacks). However, other neurological manifestations, including seizures in particular, have been repeatedly reported in APS patients. The present review will summarize recent research on the association of aPL, as well as other autoantibodies, with seizure disorders, with or without concomitant SLE.

AB - The antiphospholipid syndrome (APS) is defined by the presence of antiphospholipid antibodies (aPL), demonstrated by ELISAs for antibodies against phospholipids and associated phospholipid-binding cofactor proteins and/or a circulating lupus anticoagulant (LA) together with diverse systemic clinical manifestations such as thrombosis, and recurrent spontaneous abortions. According to the criteria set out in Sydney the only neurological manifestations that can be suitable as APS classification criteria are ischemic events (stroke and transient ischemic attacks). However, other neurological manifestations, including seizures in particular, have been repeatedly reported in APS patients. The present review will summarize recent research on the association of aPL, as well as other autoantibodies, with seizure disorders, with or without concomitant SLE.

KW - Antiphospholipid

KW - Autoantibodies

KW - Autoimmune

KW - Epilepsy

KW - Seizures

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=33646272440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646272440&partnerID=8YFLogxK

U2 - 10.1191/0961203306lu2272rr

DO - 10.1191/0961203306lu2272rr

M3 - Article

C2 - 16686257

AN - SCOPUS:33646272440

VL - 15

SP - 191

EP - 197

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 4

ER -